How to Choose a GLP-1 Provider
Rare Wellness Podcast (by Center for Regenerative and Performance Medicine) · Dr. Jamie Lewis
Audio is streamed directly from the publisher (content.rss.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr Lewis and Becca explore what you need to look for when choosing a GLP-1 Clinic.
REFERENCES
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002. doi:10.1056/NEJMoa2032183
Ashraf AR, Mackey TK, Schmidt J, et al. Safety and risk assessment of no-prescription online semaglutide purchases. JAMA Netw Open. 2024;7(8):e2428280. doi:10.1001/jamanetworkopen.2024.28280
Brown A, et al. Bridging the nutrition guidance gap for GLP-1 receptor agonist therapy assisted weight loss: lessons from bariatric surgery. International Journal of Obesity (Nature). 2025. doi:10.1038/s41366-025-01952-w
Wilding JPH, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. J Endocr Soc. 2021;5(Suppl 1):A16-A17. doi:10.1210/jendso/bvab048.030
Eshima H, et al. Unexpected effects of semaglutide on skeletal muscle mass and force-generating capacity in mice. Cell Metabolism. 2025. doi:10.1016/j.cmet.2025.07.006 [Note: cited for STEP 1 lean mass data contextualization]
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725
Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. eClinicalMedicine (The Lancet). 2025. doi:10.1016/S2589-5370(25)00614-5
GLP-1 agonists and exercise: the future of lifestyle prioritization. Frontiers in Clinical Diabetes and Healthcare. 2025. doi:10.3389/fcdhc.2025.1720794
Tinsley GM, et al. Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: a case series. PMC. 2025. (Texas Tech University IRB2025-79)
Peralta-Reich D, et al. Resistance training and protein intake may lower GLP-1 RA muscle loss. Presented at conference, 2025. Reported in Medscape Medical News, April 15, 2025.
Muñoz-Garach A, et al. Role of Vitamin D in Insulin Resistance. PMC/Nutrients. 2019. doi:10.3390/nu11061550
Lei X, Zhou Q, Wang Y, et al. Serum and supplemental vitamin D levels and insulin resistance in T2DM populations: a meta-analysis and systematic review. Scientific Reports. 2023;13(1):12343. doi:10.1038/s41598-023-39469-9
Szymczak-Pajor I, Śliwińska A. Analysis of association between vitamin D deficiency and insulin resistance. Nutrients (PMC). 2019. doi:10.3390/nu11040794
Mulligan T, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762-769. [Referenced in: Testosterone and weight loss: the evidence. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):313-322. PMC4154787]
Grossmann M. Lowered testosterone in male obesity: mechanisms, morbidity and management. Asian J Androl. 2014;16(2):223-231. PMC3955331
Corona G, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168(6):829-843. doi:10.1530/EJE-12-0955